Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EMPAGLIFLOZIN Cause Urinary tract infection? 1,439 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,439 reports of Urinary tract infection have been filed in association with EMPAGLIFLOZIN (Jardiance). This represents 3.9% of all adverse event reports for EMPAGLIFLOZIN.

1,439
Reports of Urinary tract infection with EMPAGLIFLOZIN
3.9%
of all EMPAGLIFLOZIN reports
42
Deaths
687
Hospitalizations

How Dangerous Is Urinary tract infection From EMPAGLIFLOZIN?

Of the 1,439 reports, 42 (2.9%) resulted in death, 687 (47.7%) required hospitalization, and 95 (6.6%) were considered life-threatening.

Is Urinary tract infection Listed in the Official Label?

Yes, Urinary tract infection is listed as a known adverse reaction in the official FDA drug label for EMPAGLIFLOZIN.

What Other Side Effects Does EMPAGLIFLOZIN Cause?

Diabetic ketoacidosis (3,644) Fungal infection (1,941) Blood glucose increased (1,797) Euglycaemic diabetic ketoacidosis (1,769) Weight decreased (1,661) Ketoacidosis (1,411) Dizziness (1,372) Nausea (1,333) Vomiting (1,201) Acute kidney injury (1,023)

What Other Drugs Cause Urinary tract infection?

ADALIMUMAB (6,375) LENALIDOMIDE (4,247) ETANERCEPT (3,915) OCRELIZUMAB (3,618) TOFACITINIB (3,179) METHOTREXATE (2,960) DALFAMPRIDINE (2,757) RITUXIMAB (2,579) CARBIDOPA\LEVODOPA (2,151) ABATACEPT (2,110)

Which EMPAGLIFLOZIN Alternatives Have Lower Urinary tract infection Risk?

EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\METFORMIN EMPAGLIFLOZIN vs EMSAM EMPAGLIFLOZIN vs EMTRICITABINE

Related Pages

EMPAGLIFLOZIN Full Profile All Urinary tract infection Reports All Drugs Causing Urinary tract infection EMPAGLIFLOZIN Demographics